肺動脈性肺高血圧症(Pulmonary Arterial Hypertension):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Pulmonary Arterial Hypertension - Pipeline Review, H1 2015
◆商品コード:GMDHC6252IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年3月19日
◆ページ数:181
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における肺動脈性肺高血圧症(Pulmonary Arterial Hypertension)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・肺動脈性肺高血圧症(Pulmonary Arterial Hypertension)の概要
・肺動脈性肺高血圧症(Pulmonary Arterial Hypertension)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肺動脈性肺高血圧症(Pulmonary Arterial Hypertension)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・肺動脈性肺高血圧症(Pulmonary Arterial Hypertension)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肺動脈性肺高血圧症(Pulmonary Arterial Hypertension)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Pulmonary Arterial Hypertension – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension – Pipeline Review, H1 2015’, provides an overview of the Pulmonary Arterial Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Arterial Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Pulmonary Arterial Hypertension – Overview 9
Pipeline Products for Pulmonary Arterial Hypertension – Comparative Analysis 10
Pulmonary Arterial Hypertension – Therapeutics under Development by Companies 11
Pulmonary Arterial Hypertension – Therapeutics under Investigation by Universities/Institutes 15
Pulmonary Arterial Hypertension – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pulmonary Arterial Hypertension – Products under Development by Companies 19
Pulmonary Arterial Hypertension – Products under Investigation by Universities/Institutes 23
Pulmonary Arterial Hypertension – Companies Involved in Therapeutics Development 24
Actelion Ltd 24
APT Therapeutics, Inc. 25
Arena Pharmaceuticals, Inc. 26
Asahi Kasei Pharma Corp. 27
Ascendis Pharma A/S 28
Bial – Portela & Ca, S.A. 29
Cardioxyl Pharmaceuticals, Inc. 30
Carolus Therapeutics, Inc. 31
Celladon Corporation 32
Celsion Corporation 33
Corridor Pharmaceuticals Inc. 34
Cytokinetics, Inc. 35
Eli Lilly and Company 36
Gilead Sciences, Inc. 37
HanAll Biopharma Co., Ltd. 38
Insmed Incorporated 39
Ironwood Pharmaceuticals, Inc. 40
Lacer, S.A. 41
Longevity Biotech, Inc 42
LTT Bio-Pharma Co., Ltd. 43
Mast Therapeutics, Inc. 44
Mezzion Pharma Co. Ltd. 45
miRagen Therapeutics, Inc. 46
Nippon Shinyaku Co., Ltd. 47
Novartis AG 48
PharmaIN Corporation 49
PhaseBio Pharmaceuticals, Inc. 50
Pluristem Therapeutics Inc. 51
Proteo, Inc. 52
Reata Pharmaceuticals, Inc. 53
Sagene Pharmaceuticals, Inc. 54
Silence Therapeutics plc 55
Sinoxa Pharma GmbH 56
Suda Ltd 57
Therametrics holding AG 58
Toray Industries, Inc. 59
United Therapeutics Corporation 60
Pulmonary Arterial Hypertension – Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
(allopurinol + apocynin) – Drug Profile 73
(chlorthalidone + valsartan) – Drug Profile 74
ACP-009 – Drug Profile 75
Antibody for Cancer and PAH – Drug Profile 76
Antibody for Pulmonary Arterial Hypertension – Drug Profile 77
APT-102 – Drug Profile 78
bardoxolone methyl – Drug Profile 80
beraprost sodium nanoparticles SR – Drug Profile 83
beraprost sodium SR – Drug Profile 84
BIA-51058 – Drug Profile 86
bosentan CR – Drug Profile 87
CT-2009 – Drug Profile 88
DasKloster-1000-01 – Drug Profile 89
Elafin – Drug Profile 91
esuberaprost sodium – Drug Profile 94
fasudil – Drug Profile 95
GS-4997 – Drug Profile 96
imatinib mesylate – Drug Profile 97
IW-1973 – Drug Profile 99
LA-419 – Drug Profile 100
lisuride – Drug Profile 101
macitentan – Drug Profile 103
Mydicar – Drug Profile 106
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension – Drug Profile 108
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension – Drug Profile 109
PB-1046 – Drug Profile 110
PB-1120 – Drug Profile 112
Peptide to Antagonize Urotensin-II Receptor for PAH – Drug Profile 113
PGC-VIP – Drug Profile 114
PK-10453 – Drug Profile 115
R-190 – Drug Profile 116
ralinepag – Drug Profile 118
RNAi Oligonucleotide to Inhibit miR-145 for PAH – Drug Profile 120
selegiline + PDE-5 Inhibitor – Drug Profile 121
selexipag – Drug Profile 122
Small Molecule for Pulmonary Arterial Hypertension – Drug Profile 124
Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia – Drug Profile 125
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction – Drug Profile 126
Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension – Drug Profile 127
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension – Drug Profile 128
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension – Drug Profile 129
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension – Drug Profile 130
sodium nitrite – Drug Profile 131
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 133
SUD-004 – Drug Profile 135
Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension – Drug Profile 136
tadalafil – Drug Profile 137
TPN-171 – Drug Profile 139
treprostinil diolamine – Drug Profile 140
TXA-127 – Drug Profile 141
udenafil – Drug Profile 143
Pulmonary Arterial Hypertension – Recent Pipeline Updates 145
Pulmonary Arterial Hypertension – Dormant Projects 168
Pulmonary Arterial Hypertension – Discontinued Products 169
Pulmonary Arterial Hypertension – Product Development Milestones 170
Featured News & Press Releases 170
Appendix 176
Methodology 176
Coverage 176
Secondary Research 176
Primary Research 176
Expert Panel Validation 176
Contact Us 176
Disclaimer 177

[List of Tables]
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2015 13
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Development by Companies, H1 2015 (Contd..3) 26
Products under Investigation by Universities/Institutes, H1 2015 27
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H1 2015 28
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H1 2015 29
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 30
Pulmonary Arterial Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2015 31
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2015 32
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2015 33
Pulmonary Arterial Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 34
Pulmonary Arterial Hypertension - Pipeline by Carolus Therapeutics, Inc., H1 2015 35
Pulmonary Arterial Hypertension - Pipeline by Celladon Corporation, H1 2015 36
Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H1 2015 37
Pulmonary Arterial Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 38
Pulmonary Arterial Hypertension - Pipeline by Cytokinetics, Inc., H1 2015 39
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2015 40
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H1 2015 41
Pulmonary Arterial Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 42
Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H1 2015 43
Pulmonary Arterial Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 44
Pulmonary Arterial Hypertension - Pipeline by Lacer, S.A., H1 2015 45
Pulmonary Arterial Hypertension - Pipeline by Longevity Biotech, Inc, H1 2015 46
Pulmonary Arterial Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 47
Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H1 2015 48
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 49
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2015 50
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 51
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2015 52
Pulmonary Arterial Hypertension - Pipeline by PharmaIN Corporation, H1 2015 53
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 54
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2015 55
Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H1 2015 56
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 57
Pulmonary Arterial Hypertension - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 58
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics plc, H1 2015 59
Pulmonary Arterial Hypertension - Pipeline by Sinoxa Pharma GmbH, H1 2015 60
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2015 61
Pulmonary Arterial Hypertension - Pipeline by Therametrics holding AG, H1 2015 62
Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H1 2015 63
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corporation, H1 2015 64
Assessment by Monotherapy Products, H1 2015 65
Assessment by Combination Products, H1 2015 66
Number of Products by Stage and Target, H1 2015 68
Number of Products by Stage and Mechanism of Action, H1 2015 71
Number of Products by Stage and Route of Administration, H1 2015 74
Number of Products by Stage and Molecule Type, H1 2015 76
Pulmonary Arterial Hypertension Therapeutics - Recent Pipeline Updates, H1 2015 149
Pulmonary Arterial Hypertension - Dormant Projects, H1 2015 172
Pulmonary Arterial Hypertension - Discontinued Products, H1 2015 173

[List of Figures]
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2015 13
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Products, H1 2015 22
Assessment by Monotherapy Products, H1 2015 65
Assessment by Combination Products, H1 2015 66
Number of Products by Top 10 Targets, H1 2015 67
Number of Products by Stage and Top 10 Targets, H1 2015 67
Number of Products by Top 10 Mechanism of Actions, H1 2015 70
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 70
Number of Products by Top 10 Routes of Administration, H1 2015 73
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 74
Number of Products by Top 10 Molecule Types, H1 2015 75
Number of Products by Stage and Top 10 Molecule Types, H1 2015 76

【掲載企業】

Actelion Ltd
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Ascendis Pharma A/S
Bial - Portela & Ca, S.A.
Cardioxyl Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Celladon Corporation
Celsion Corporation
Corridor Pharmaceuticals Inc.
Cytokinetics, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
HanAll Biopharma Co., Ltd.
Insmed Incorporated
Ironwood Pharmaceuticals, Inc.
Lacer, S.A.
Longevity Biotech, Inc
LTT Bio-Pharma Co., Ltd.
Mast Therapeutics, Inc.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc.
Reata Pharmaceuticals, Inc.
Sagene Pharmaceuticals, Inc.
Silence Therapeutics plc
Sinoxa Pharma GmbH
Suda Ltd
Therametrics holding AG
Toray Industries, Inc.
United Therapeutics Corporation

★調査レポート[肺動脈性肺高血圧症(Pulmonary Arterial Hypertension):治療薬開発パイプライン動向(2015年上半期版)] (コード:GMDHC6252IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[肺動脈性肺高血圧症(Pulmonary Arterial Hypertension):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆